



VARS2 and TARS2Mutations in Patients with
Mitochondrial Encephalomyopathies
Daria Diodato,1 † Laura Melchionda,1 † Tobias B. Haack,2,3 Cristina Dallabona,4 Enrico Baruffini,4 Claudia Donnini,4
Tiziana Granata,5 Francesca Ragona,5 Paolo Balestri,6 Maria Margollicci,6 Eleonora Lamantea,1 Alessia Nasca,1
Christopher A. Powell,7 Michal Minczuk,7 Tim M. Strom,2,3 Thomas Meitinger,2,3 Holger Prokisch,2,3 Costanza Lamperti,1
Massimo Zeviani,1,7 and Daniele Ghezzi1∗
1Unit of Molecular Neurogenetics, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) Istituto Neurologico “Carlo Besta”,
Milan, Italy; 2Institute of Human Genetics, Helmholtz Zentrum Mu¨nchen, Neuherberg, Germany; 3Institute of Human Genetics, Technische
Universitat Mu¨nchen, Munich, Germany; 4Department of Life Sciences, University of Parma, Parma, Italy; 5Unit of Child Neurology, Fondazione
IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy; 6Department of Pediatrics, University of Siena, Siena, Italy; 7MRC Mitochondrial Biology
Unit, Cambridge, United Kingdom
Communicated by Daniel W. Nebert
Received 25 November 2013; accepted revised manuscript 29 April 2014.
Published online 14 May 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22590
ABSTRACT: By way of whole-exome sequencing, we iden-
tified a homozygous missense mutation in VARS2 in one
subject with microcephaly and epilepsy associated with
isolated deficiency of the mitochondrial respiratory chain
(MRC) complex I and compound heterozygous mutations
in TARS2 in two siblings presenting with axial hypoto-
nia and severe psychomotor delay associated with mul-
tiple MRC defects. The nucleotide variants segregated
within the families, were absent in Single Nucleotide
Polymorphism (SNP) databases and are predicted to be
deleterious. The amount of VARS2 and TARS2 pro-
teins and valyl-tRNA and threonyl-tRNA levels were
decreased in samples of afflicted patients according to
the genetic defect. Expression of the corresponding wild-
type transcripts in immortalized mutant fibroblasts rescued
the biochemical impairment of mitochondrial respiration
and yeast modeling of the VARS2 mutation confirmed its
pathogenic role. Taken together, these data demonstrate
the role of the identified mutations for these mitochon-
driopathies. Our study reports the first mutations in the
VARS2 and TARS2 genes, which encode two mitochon-
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drial aminoacyl-tRNA synthetases, as causes of clinically
distinct, early-onset mitochondrial encephalopathies.
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Introduction
Mitochondrial disorders include widely heterogeneous clinical
syndromes, frequently presenting as encephalo- and/or cardiomy-
opathies, associated with a broad range of causative genes [Ghezzi
and Zeviani, 2012]. Their biochemical signature is the presence of
defective activity in the mitochondrial respiratory chain (MRC)
complexes, resulting in faulty oxidative phosphorylation (OX-
PHOS), which can impair ATP production. Mutations in several
genes associated with defects of mitochondrial protein synthesis,
affecting either mitochondrial DNA (mtDNA) or nucleus-encoded
genes, have been reported in a range of mitochondrial syndromes
[Rotig, 2011].
Translation of the 13 mtDNA-encoded, OXPHOS-related pro-
teins takes place within the mitochondrial matrix. This complex
process requires ribosomal and transfer RNAs (rRNAs and tRNAs),
encoded by mtDNA, and more than 100 proteins, encoded by nu-
clear genes, translated by cytosolic ribosomes and imported into
mitochondria. These include aminoacyl-tRNA synthetases (aaRSs),
ribosomal proteins, ribosomal assembly factors, tRNA- and rRNA-
modifying enzymes, initiation, elongation, and termination factors
[Smits et al., 2010]. Mutations in any component of the mito-
chondrial translation machinery can in principle cause inherited
mitochondrial disorders affecting the MRC complexes containing
mtDNA-encoded subunits (cI, cIII, cIV, cV), with the preservation
of complex II, the only complex which has no mtDNA-encoded
proteins.
An increasing number of mitochondrial translation disorders are
caused by mutations in genes encoding mt-aaRSs [Konovalova and
Tyynismaa, 2013], which catalyze the ligation of specific amino acids
C© 2014 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
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Figure 1. Patients’ phenotypical, biochemical, and mutational features. A–C: Axial (A, B) and sagittal (C) T2-weighted images of patient 1, taken
at 4 years of age. A: Note T2-hyperintense lesions in the frontotemporal right cortex. There are also signal abnormalities in the semioval center
(B) and the insula (C). D: Pedigree of patients 2 and 3. Black symbols designate affected subjects. E: Bar graphs with MRC complex activities in P1
muscle homogenate. I, II, III, IV, and V correspond to the activities of complexes I, II, III, IV, and V, respectively, normalized for the citrate synthase
activity. F: Bar graphs with MRC complex activities in P2 muscle homogenate. I, II, III, IV, and V correspond to the activities of complexes I, II, III,
IV, and V, respectively, normalized for the citrate synthase activity.
to their cognate tRNAs, a crucial process for faithful protein synthe-
sis. Mitochondrial and cytoplasmic aaRSs are encoded by distinct
nuclear genes, with the exception of GARS and KARS, which are
present in both cellular compartments. The term aaRS2 indicates
the gene coding for the mitochondrial enzyme. Mutations in aaRS2
genes have been associated with diverse clinical presentations, usu-
ally characterized by early-onset and autosomal recessive transmis-
sion. A relatively tight genotype–phenotype correlation has been
reported for most of these syndromes, although the basis of cell-
or tissue-specific damage remains unclear, since all mt-aaRSs are
ubiquitous enzymes operating in the same pathway [Rotig, 2011].
We report here the identification by whole-exome sequencing
(WES) of the first described mutations in VARS2 (MIM# 612802)
and TARS2 (MIM# 612805) in patients with clinical presentations
compatible with mitochondrial disorders and OXPHOS deficiency.
All identified variants were not present in SNPs databases, pre-
dicted to be deleterious, segregated within the families, and associ-
ated with decreased aminoacylation of the corresponding tRNAs in
mutant immortalized fibroblasts; moreover, their pathogenic role
was proven by using complementation assays on immortalized fi-
broblasts from patients and, for the VARS2 mutation, on a specific
recombinant yeast model.
Patients and Methods
Informed consent, approved by the Ethical Committee of the
Foundation IRCCS Istituto Neurologico “C.Besta”, Milan, Italy, in
agreement with the Declaration of Helsinki, was signed by the par-
ents of the patients.
Patient 1 (P1)
P1 is an 8-year-old patient, born at the 37th week of gestation
by normal delivery. Early after birth, he showed psychomotor de-
lay, facial dysmorphisms, and microcephaly. He never achieved au-
tonomous ambulation. At 4 years of age, onset of partial seizures
was characterized by version of the head towards right, followed by
clonic and tonic movements initially involving the right arm and
subsequently the left one. Between the episodes of focal seizures,
bilateral asynchronous myoclonic jerks, in the form of epilepsia
partialis continua, involved both upper limbs. On several occasions,
seizures evolved into status epilepticus.
Brain MRI displayed hyperintense lesions in the periventricular
regions, the insulae, and the frontotemporal right cortex (Fig. 1A–
C). Brain protonmagnetic resonance spectroscopy revealed a lactate
peak in the frontalwhitematter. EEGshowedslowbackgroundactiv-
ity and epileptic abnormalities in the frontotemporal and occipital
derivations of both sides (R > L). Muscle computerized tomography
showed bilateral quadriceps hypotrophy but no evident histological
alteration was observed in a muscle biopsy.
Patients 2 and 3 (P2, P3)
P2 and P3 were two siblings (Fig. 1D) presenting with axial hy-
potonia and limb hypertonia, psychomotor delay, and high levels of
blood lactate. They both died a fewmonths after birth of ametabolic
crisis.
The brain MRI of P2 at 5 months of age showed a thin cor-
pus callosum and hyperintense lesions of the globi pallidi (images
not available); no clear alterations were present in the MRI of P3,
taken at 3 months of age. Autoptic examination was carried out
on P2 and revealed subsarcolemmal lipofuscin-positive deposits at
the trichrome Gomori staining of muscle, cerebral spongiosis, and
hepatic steatosis.
Biochemical Studies
Biochemical measurement of individual OXPHOS complex ac-
tivities was performed by standard spectrophotometric assays [Bu-
giani et al., 2004] in muscle homogenate and digitonin-treated
skin fibroblasts. Oxygen consumption rate was measured using a
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SeaHorse FX-96 apparatus (Bioscience, Copenhagen, Denmark)
[Invernizzi et al., 2012] in fibroblasts grown either in glucose-rich
or in 5 mM galactose, glucose-free DMEM medium for 72 h.
Molecular Analysis
Total genomic DNAwas extracted by standard methods from pe-
ripheral blood lymphocytes or muscle biopsies. Southern blot anal-
ysis of muscle mtDNA and sequencing of the entire mtDNA was
performed as described [He et al., 2002]. WES and variant filtering
were performed as previously reported [Haack et al., 2012]. Exons
and exon–intron boundaries of human VARS2 (NM 001167734.1;
NP 001161206.1) and TARS2 (NM 025150.4; NP 079426.2) were
amplified using primers listed in Supp. Table S1, and analyzed by
Sanger sequencing. Nucleotide numbering reflects cDNA num-
bering with +1 corresponding to the A of the ATG translation
initiation codon in the reference sequence, as indicated in the
guidelines of this journal (www.hgvs.org/mutnomen). The initia-
tion codon is codon 1. All variants reported have been submitted
to LSDB (http://www.lovd.nl/VARS2; http://www.lovd.nl/TARS2).
Total RNA was isolated from cell pellets using the RNeasy Mini
Kit (Qiagen, Milan, Italy) and reverse transcribed to cDNA using
the GoTaq R© 2-Step RT-qPCR System (Promega, Madison, WI),
followingmanufacturer’s recommendations.VARS2 and TARS2 ex-
pression in DNase-treated cDNA samples was determined using
reverse transcription quantitative PCR with specific amplicons and
SYBR-green chemistry (Supp. Table S1).
Western Blot Analysis
Approximately 106 cells from patients and controls were
trypsinized, pelleted, sonicated, and solubilized, as described else-
where [Tiranti et al., 1999]. SDS-polyacrylamide gel of 50 μg pro-
tein/lane and Western blot analysis were performed using antibod-
ies against VARS2 (Mitosciences, Eugene, OR), TARS2 (GeneTex,
Irvine, CA), and HSP60 (Abcam).
tRNA Aminoacylation Assay
Total RNA was extracted from fibroblasts using Trizol reagent
(Life Technologies, Carlsbad, CA) following the manufacturer’s in-
structions, with the final pellet resuspended in 10 mM NaOAc at
pH 5.0 and kept at 4°C to preserve the aminoacylation state. For
the deacylated control, the pellet was resuspended in 200 mM Tris-
HCl at pH 9.5 and incubated at 75°C for 5 min, followed by RNA
precipitation and resuspension in 10 mM NaOAc at pH 5. Fifteen
micrograms of each RNA sample was separated by acid-urea PAGE
as described previously [Ko¨hrer and RajBhandary, 2008] and elec-
troblotted to a nylon membrane at 400 mA for >6 h in 40 mM Tris-
HCl, pH 8.0, and 2 mM EDTA. Following UV cross-linking (0.120
J), the membrane was hybridized with appropriate radiolabeled ri-
boprobes [Minczuk et al., 2011]. Northern blots were quantified
by PhosphorImager analysis with ImageQuant software (Molecular
Dynamics, Sunnyvale, CA).
Lentiviral Transduction
The wild-type (wt) cDNAs from VARS2 or TARS2 were cloned
into thepLenti6.3/V5-TOPOVector (LifeTechnologies), andvirions
were obtained as previously described [Zhang et al., 2009]. Fibrob-
lasts were immortalized with pRNS-1 by a lipofectin transfection
[Litzkas et al., 1984]. Mutant and wt immortalized fibroblasts were
infected with viral supernatant and selected upon exposure to 2
μg/ml Blasticidin (Life Technologies).
Yeast Studies
Adetaileddescriptionof culturemedia, plasmids, and strainsused
for yeast studies is reported in theSupp.Methods,withprimers listed
in Supp. Table S2. Yeast growth, respiratory activity, and in vitro
mtDNA protein synthesis were performed as previously described
[Barrientos et al., 2009; Goffrini et al., 2009]. Division time and
respiration were measured after growth in SD medium without
valine or with valine 40 μg/ml, while mtDNA protein synthesis
was measured after growth on SC medium supplemented with 2%
galactose and 0.2% glucose.
Results
Biochemical Findings
Biochemical assays of MRC complex activities revealed an iso-
lated complex I deficiency (25% of residual activity) in muscle ho-
mogenate of P1 (Fig. 1E), but no enzymatic defects in fibroblasts.
However, oxygen consumption performed in P1 fibroblasts cultured
in either glucose or galactose medium showed defective respiration
rate compared to control (Supp. Fig. S1).
Biochemical analysis of P2 showed multiple deficiency of the
MRC complex activities in muscle homogenate (Fig. 1F), whereas
no defect was observed in fibroblasts; P3 muscle showed the same
multiple defect, whereas theMRCcomplex activitieswere all normal
in a postmortem liver specimen. Oxygen consumption rate of P2
fibroblasts was in the control range in glucose medium, but lower
than normal in galactose medium, compared to control cells (Supp.
Fig. S1). No fibroblasts were available from P3.
Mutation Detection
In all patients, mtDNA sequencing revealed no pathogenic mu-
tations and Southern blot analysis was negative for mtDNA dele-
tions or depletion. We then looked for mutations in nuclear genes
by WES, performed on genomic DNA from P1 and P3. After fil-
tering to exclude common SNPs (>0.1%), the remaining nonsyn-
onymous/splice site (NS/SS) changes andmicroinsertions/deletions
(INS/DEL) were prioritized according to the presence of homozy-
gous or compound heterozygous mutations, as expected for reces-
sive transmission suggested by the structure of our pedigrees, and
for known or predicted mitochondrial localization of the corre-
sponding protein [Elnster et al., 2008; Haack et al., 2012; Ghezzi
et al., 2012].
In P1, the filtration strategy revealed the presence of a ho-
mozygous missense mutation (c.1100C>T, p.Thr367Ile, Fig. 2A) in
VARS2, the gene encoding themitochondrial valyl tRNA-synthetase.
Thr367 is conserved in several species, including yeast (Supp. Fig.
S2), and the change Thr367Ile has high scores for pathogenicity
according to different bioinformatic tools (Supp. Table S3). The
mutation was present in heterozygous state in both parents.
Following identical procedures for P3 analysis, we identified two
variants in TARS2, encoding the mitochondrial threonyl tRNA-
synthetase: amissensemutation (c.845C>T, p.Pro282Leu) and a nu-
cleotide change in position +3 of intron 6 (g.4255A>G; c.695+3A>G)
(Fig. 2B–C). Both changes were present also in his affected sister P2,
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Figure 2. Molecular and protein characterization of VARS2 and TARS2 mutations. A: Electropherogram of the VARS2 genomic region encom-
passing the c.1100C>T nucleotide substitution in patient 1. B–C: Electropherograms of the TARS2 genomic regions encompassing the c.845C>T
(B) and c.695+3A>G (C) nucleotide substitutions in patient 3. D: Western Blot analysis of fibroblasts from patient 1 (P1) and control fibroblasts
(Ct) using antibodies against VARS2 and HSP60; the latter was taken as a loading control. The reported percentages correspond to the values of
VARS2/HSP60 signals obtained by densitometric analysis in three independent experiments. E: Western Blot analysis of fibroblasts from patient
2 (P2) and control fibroblasts (Ct) using antibodies against TARS2 and HSP60 proteins; the latter was taken as a loading control. The reported
percentages correspond to the values of TARS2/HSP60 signals obtained by densitometric analysis in three independent experiments. F: Aminoa-
cylation levels of mitochondrial tRNAVal, tRNAThr, and tRNALeuUUR in control, patient 1 (P1), and patient 2 (P2) fibroblasts measured by quantification
of Northern blots (Supp. Fig. S4) performed as described in the Patients and Methods section.
and are predicted to be deleterious (Supp. Table S3). Father and
mother were heterozygous carriers for the SS and the missense mu-
tation, respectively; one healthy sibling was heterozygous for the
SS mutation, while the other was negative for both. Pro282 is con-
served in mammals and bird, and present in the yeast Ths1 (Supp.
Fig. S2), corresponding to the cytosolic, and possibly also to a mito-
chondrial, threonyl-tRNA synthetase. All the identified nucleotide
substitutions were not reported in public databases, including db-
SNPs and NHLBI Exome Sequencing Project.
Analysis of VARS2 and TARS2 Transcripts, Protein Levels,
and Aminoacylation of Cognate Mitochondrial tRNAs
As expected, the homozygous missense mutation did not alter
the VARS2 transcript levels in P1 fibroblasts (Supp. Fig. S3). How-
ever, the amount of the VARS2 protein detected by Western blot
analysis was moderately decreased compared to control fibroblasts,
suggesting partial instability of the mutant protein (Fig. 2E).
In order to evaluate the effect of the intronic variant on TARS2
transcript, we amplified cDNAs extracted from P2 and control fi-
broblasts. In P2, we did not detect any aberrant species but the band
corresponding to the full-length transcript was found to contain
only the mutated nucleotide T in position c.845, suggesting that the
intronic mutation in the SS determines an aberrant and highly un-
stable TARS2 transcript (Supp. Fig. S3). Quantitative real-time PCR
analysis revealed diminished expression of TARS2 (Supp. Fig. S3)
andWestern Blot analysis showed a clear decrease in TARS2 protein
in P2 fibroblasts compared to controls, confirming the hypothesis
on the null contribution of the allele with the intronic mutation
(Fig. 2F).
Next, we measured the levels of aminoacylated tRNAs (threonyl-
tRNA, valyl-tRNA, and leucyl-tRNA as a control) in P1, P2, and
a control fibroblast line. In P1, charged tRNAVal was moderately
decreased compared to control fibroblasts. Severe decrease in the
aminoacylated tRNAThr was observed in P2 fibroblasts. No appre-
ciable difference in aminoacylation level was found for leucyl-tRNA
between control, P1, and P2 fibroblasts (Fig. 2F; Supp. Fig. S4).
Yeast Studies
To test the possible deleterious effect of the mutations found
in humans, we used a Saccharomyces cerevisiae yeast model. How-
ever, this investigation was possible only for the VARS2 but not
for the TARS2 gene. Yeast has two genes encoding threonyl-tRNA
synthetases, THS1 andMST1. THS1 encodes a cytoplasmic isoform
and a putativemitochondrial isoform,which aminoacylates only the
canonical tRNAThr(UGU);MST1 encodes the mitochondrial isoform,
which aminoacylates both mt-tRNAThr(UGU) and the noncanonical
mt-tRNAThr(UAG), whose corresponding CUN codon encodes, in
yeast but not in humans, threonine instead of leucine [Su et al.,
2011; Ling et al., 2012]. The human Pro282 is conserved in Ths1,
but not in Mst1, which lacks the N-terminal region containing this
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Figure 3. Yeast growth studies. Growth of cytvas1 strain transformed with wt VAS1, vas1T380I mutant allele or empty plasmid on SD medium
supplemented with 2% glucose (SDD, left panel) or 2% ethanol (SDE, right panel). Cells were pregrown on SDD and plated after serial dilutions to
obtain spots of 5 × 104, 5 × 103, 5 × 102, and 5 × 101 cells/spot. Pictures were taken after 2 days of growth on SDD and 3 days on SDE. Colonies
spotted on the third spot of SDE were magnified with a Leica LM 2000 microscope. Division time was calculated by growing cells on liquid SDE
medium and measuring the optical density at 600 nm every 2 h when cells were in log phase of growth. Values are mean of three independent
experiments. ∗P < 0.05 by using a two-tailed, paired t-test.
amino acid. Introduction of the corresponding mutation in THS1
would not affect mtDNA-dependent protein synthesis, since the
mitochondrial enzyme Mst1 is present and can aminoacylate all
the mt-tRNAThr, whereas introduction of mutant (or wt) THS1 in
a MST1 strain would not allow the mtDNA-dependent protein
synthesis since the mt-tRNAThr(UAG) would not be aminoacylated,
and CUN codons would not be translated.
Contrariwise, the mutated Thr367 residue in human VARS2
is conserved in the yeast ortholog VAS1 (Thr380). However,
VAS1 codes for both the cytosolic and mitochondrial valyl tRNA-
synthetases.We disruptedVAS1 by homologous recombination and
reexpressed the wt cytosolic isoform, thus generating a viable but
OXPHOS incompetent strain (cytvas1), which lacked themitochon-
drial isoform. In this strain, we expressed either the wt VAS1 gene
(VAS1), or a Thr380Ile mutant allele (vas1T380I), equivalent to the
human Thr367Ile mutation (Supp. Fig. S2).
The strain expressing vas1T380I showed a division time in ethanol
higher than the strain expressing VAS1 (Fig. 3), suggesting an
OXPHOS-dependent growth defect. Accordingly, the respiration
rate in vas1T380I strain was slightly but significantly lower than in
VAS1 strain (Supp. Fig. S5). No obvious alterations were observed
in the in vivo mitochondrial protein synthesis assay (Supp. Fig. S5).
Interestingly, the supplementation of valine (40 μg/ml) in the cul-
ture medium led to normalization of the division time (Fig. 3) and
recovery of respiration for vas1T380I strain (Supp. Fig. S5), suggesting
that Thr380 maps to the substrate binding site and its substitution
with Ile380 yields a Km defect.
Complementation Studies in Fibroblasts
To validate the pathogenic role of the identified variants, we
sought for the presence of a biochemical readout of mutant fi-
broblasts by measuring the oxygen consumption rate in cells grown
in a galactose-rich, glucose-free medium, a condition that forces
cells to depend on mitochondrial respiration rather than glycolysis
for ATP production. To avoid discrepancies in the measurements,
due to culture passages of primary fibroblasts, we used immortal-
ized P1 and P2 cell lines. We found a clear decrease in the maximal
respiration rate in both P1 and P2 immortalized cells compared to
immortalized control fibroblasts, which increased to normal values
after transduction with a recombinant lentiviral construct express-
ing the wt cDNA of either VARS2 (for P1, and the corresponding
control) or TARS2 (for P2, and the corresponding control) (Fig. 4A
and B). Western blot on P1 and P2 fibroblasts after transduction
showed an increase in the amount of VARS2 and TARS2 proteins,
respectively (Fig. 4C and D).
These results confirm the causative role for VARS2 and TARS2
variants in defective mitochondrial respiration of P1 and P2 cells,
respectively.
Discussion
Mutations in genes coding for mitochondrial aminoacyl-tRNA
synthetases have been associated with diverse clinical presenta-
tions, usually inherited as early-onset autosomal recessive traits
[Konovalova and Tyynismaa, 2013]. We and others have reported
a strict genotype–phenotype correlation for most of these condi-
tions [Edvardson et al. 2007; Scheper et al., 2007; Sasarman et al.
2012; Steenweg et al., 2012]. Since these genetic defects involve
ubiquitously expressed enzymes all engaged in the very same en-
zymatic step of mitochondrial translation, the mechanisms leading
to such different cellular and tissue-specific phenotypes remain un-
explained. Different hypotheses have been proposed to elucidate
the clinical variability associated with different aaRS2 mutations,
but none seems to explain all aspects of this phenomenon that is
probably the result of several mechanisms altered in aaRS2 mutant
patients [Konovalova and Tyynismaa, 2013].
However, and similar to our VARS2 and TARS2mutations, most
mutations in aaRS2 genes have been reported in single, or in just
a few, cases, which hampers the establishment of definitive geno-
type to phenotype correlation. For instance, AARS2mutations were
initially described as associated with hypertrophic cardiomyopa-
thy in two families, but were later found also in patients with
leukoencephalopathy and no heart involvement [Dallabona et al.,
2014]. Nevertheless, encephalopathy is the most common presen-
tation in aaRS2 mutations, as in several other OXPHOS disorders,
probably because of the high energy request by the central ner-
vous system. For instance, mutations in DARS2 (MIM# 610956)
(mitochondrial aspartyl-tRNA synthetase) have been identified as
a recurrent cause of leukoencephalopathy with brainstem, spinal
HUMAN MUTATION, Vol. 35, No. 8, 983–989, 2014 987
Figure 4. Complementation studies in mutant fibroblasts. A: Oxygraphy performed in immortalized P1 and control fibroblasts cultured in
galactose medium in naı¨ve condition and after infection with wt cDNA of VARS2 (+VARS2). Y-axis values correspond to the maximal respiration
rate, expressed as pMolesO2/min/cell. Data are represented as mean ± SD. Two-tail, paired t-test was applied for statistical significance. ∗∗∗P <
0.001; ns: nonsignificant (P> 0.01).B: Oxygraphyperformed in immortalizedP2andcontrol fibroblasts cultured in galactosemedium in naı¨ve condition
and after infection with wt cDNA of TARS2 (+TARS2). Y-axis values correspond to the maximal respiration rate, expressed as pMolesO2/min/cells.
Data are represented as mean ± SD. Two-tail, paired t-test was applied for statistical significance. ∗∗∗P < 0.001; ns: nonsignificant (P > 0.01).
C: Western blot analysis of samples reported in Figure 4A using antibodies against VARS2 and HSP60, the latter being taken as a loading control.
D: Western blot analysis of samples reported in Figure 4B using antibodies against TARS2 and HSP60, the latter being taken as a loading control.
cord involvement, and lactate elevation, whereas EARS2 mutations
(MIM# 612799) (mitochondrial glutamyl-tRNA synthetase) are as-
sociated with a leukoencephalopathy with thalamus and brainstem
involvement and high lactate. Pontocerebellar hypoplasia 6, a severe
infantile encephalopathy with cerebral atrophy and multiple OX-
PHOS deficiency, is associated with RARS2 (MIM# 611524) (mito-
chondrial arginyl-tRNAsynthetase)mutations.Complex rearrange-
ments inMARS2 (mitochondrial methionyl-tRNA synthetase) were
described in a cohort of patients with autosomal recessive spas-
tic ataxia with leukoencephalopathy, whereas mutations in FARS2
(MIM# 611592) (Phenylalanyl-tRNA synthetase) were identified in
three patients with fatal epileptic mitochondrial encephalopathy,
consistent with Alpers’ syndrome. Interestingly, specific MRI pat-
terns seem to be associated with some aaRS2 (e.g., DARS2, EARS2,
RARS2) mutant patients. In our cases, P1 MRI showed hyperin-
tense lesions involving mainly the insulae and frontotemporal right
cortex, whereas P2 MRI was reported to show thinning of corpus
callosum (a neuroimaging finding common to several neurodegen-
erative disorders) and bilateral lesions of the globi pallidi. However,
the MRI of P3, brother of P2, was normal, although this can be due
to the very early age at which this exam was performed. Additional
VARS2 and TARS2 cases will clarify whether these MRI patterns are
specific or not.
Mutations in aaRS2, impairing the translation of the 13 mtDNA-
encoded MRC subunits, should in principle be associated with a
biochemical deficiency of all MRC complexes, except cII. This bio-
chemical profile was indeed found in muscle samples from the two
TARS2 mutant subjects (P2 and P3), whereas the VARS2 mutant
muscle (P1) showed isolated cI deficiency. Complex I seems to be
particularly prone to damage in mtDNA translation defects, as al-
ready reported for MARS2 in patients’ cells and in the correspond-
ing mutant fly model [Bayat et al., 2012] or for mutations in other
proteins involved in mitochondrial protein synthesis, such as mito-
chondrial methionyl-tRNA-formyltransferase [Haack et al., 2012].
This propensity can partly be explained by the fact that seven of the
13mtDNA-encoded proteins are subunits of cI, and by the complex-
ity of its functional and structural interactions. In patients’ fibrob-
lasts, biochemical assays of individual MRC complexes showed in-
consistent alterations, indicating partial preservation of functional
proficiency of the mutant enzyme or reflecting the (partial) dis-
pensability from OXPHOS of this cell type. The same biochemical
discrepancy has also been reported for mutations in other mt-aaRSs
[Gotz et al., 2011; Bayat et al., 2012; Sasarman et al., 2012]. How-
ever, we observed a consistent biochemical phenotype in both naı¨ve
and immortalized mutant fibroblasts by measuring whole mito-
chondrial respiration, especially in culturing conditions that force
cells to rely on OXPHOS to produce energy. As already reported for
EARS2 mutant fibroblasts, a diminished oxygen consumption rate
is likely to depend on the cumulative impairment of the entire set of
MRC complexes [Steenweg et al., 2012]. We proved the pathogenic
role of the mutations identified in VARS2 and TARS2 by showing
decreased levels of aminoacylation of the cognate mitochondrial
tRNAs and by complementing the biochemical defects in patients’
fibroblasts expressing the corresponding wt cDNAs. This evidence
was further corroborated for the VARS2 mutation by concordant
results obtained in a recombinant yeast model.
In conclusion, we identified novel mutations in two genes en-
coding mitochondrial aminoacyl-tRNA synthetases (VARS2 and
TARS2), which have not been appreciated previously as causing
mitochondrial disease, thus expanding the list of aaRS2-associated
diseases. We also confirmed the value of WES for the identifica-
tion of disease-causing genes even in single patients presenting het-
erogeneous clinical syndromes but with a biochemically detectable
“mitochondrial signature.”
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